
Jason H Karnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/629/publications.pdf Version: 2024-02-01



LASON H KADNES

#	Article	IF	CITATIONS
1	From Big Data to Precision Medicine. Frontiers in Medicine, 2019, 6, 34.	2.6	273
2	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
3	Biobanks and Electronic Medical Records: Enabling Cost-Effective Research. Science Translational Medicine, 2014, 6, 234cm3.	12.4	118
4	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Science Translational Medicine, 2017, 9, .	12.4	105
5	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLAâ€B</i> Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
6	Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy, 2017, 37, 1150-1163.	2.6	77
7	Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug-Induced Long QT Interval Syndrome. Journal of the American College of Cardiology, 2014, 63, 1430-1437.	2.8	70
8	Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444.	2.5	58
9	Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenetics and Genomics, 2017, 27, 247-254.	1.5	54
10	Genome-Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1421-1432.	5.6	50
11	A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record. Thrombosis and Haemostasis, 2015, 113, 772-781.	3.4	49
12	A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics Journal, 2016, 16, 231-237.	2.0	47
13	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2019, 59, 463-486.	9.4	42
14	Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood, 2016, 128, 3043-3051.	1.4	35
15	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	6.7	31
16	Immunopharmacogenomics: Mechanisms of HLAâ€Associated Drug Reactions. Clinical Pharmacology and Therapeutics, 2021, 110, 607-615.	4.7	29
17	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Review of Cardiovascular Therapy, 2009, 7, 689-702.	1.5	28
18	Clinical and Genetic Factors Associated With Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients. Transplantation Direct, 2015, 1, 1-7.	1.6	26

JASON H KARNES

#	Article	IF	CITATIONS
19	Innovation in Clinical Pharmacy Practice and Opportunities for Academic–Practice Partnership. Pharmacotherapy, 2014, 34, e45-54.	2.6	24
20	Factors Influencing Blood Pressure Response to Trandolapril Add-On Therapy in Patients Taking Verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). American Journal of Cardiology, 2007, 99, 1549-1554.	1.6	22
21	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19
22	Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics Journal, 2013, 13, 430-436.	2.0	18
23	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	5.6	18
24	Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 125-135.	6.6	17
25	Racial, ethnic, and gender differences in obesity and body fat distribution: An All of Us Research Program demonstration project. PLoS ONE, 2021, 16, e0255583.	2.5	16
26	Psychological and Genetic Predictors of Pain Tolerance. Clinical and Translational Science, 2019, 12, 189-195.	3.1	15
27	Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data. PLoS ONE, 2013, 8, e81503.	2.5	15
28	Influence of Human Leukocyte Antigen (<scp>HLA</scp>) Alleles and Killer Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) Types on Heparinâ€Induced Thrombocytopenia (<scp>HIT</scp>). Pharmacotherapy, 2017, 37, 1164-1171.	2.6	14
29	A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nature Communications, 2018, 9, 3522.	12.8	13
30	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics, 2013, 23, 697-705.	1.5	12
31	Identifying genetically driven clinical phenotypes using linear mixed models. Nature Communications, 2016, 7, 11433.	12.8	12
32	Comparison of family health history in surveys vs electronic health record data mapped to the observational medical outcomes partnership data model in the <i>All of Us</i> Research Program. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 695-703.	4.4	11
33	Single nucleotide polymorphisms in the MYLKP1 pseudogene are associated with increased colon cancer risk in African Americans. PLoS ONE, 2018, 13, e0200916.	2.5	10
34	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	1.0	10
35	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Frontiers in Pharmacology, 2021, 12, 749786.	3.5	10
36	<scp><i>PROX1</i></scp> Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment. Pharmacotherapy, 2014, 34, 123-130.	2.6	9

JASON H KARNES

#	Article	IF	CITATIONS
37	Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. Clinical and Translational Science, 2021, 14, 2532-2543.	3.1	9
38	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	1.4	9
39	Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?. Pharmacogenomics, 2018, 19, 1413-1422.	1.3	8
40	Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site. Clinical and Translational Science, 2020, 13, 685-692.	3.1	7
41	Multiâ€site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clinical and Translational Science, 2021, 14, 268-276.	3.1	7
42	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146.	5.2	7
43	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	4.7	6
44	Geographic Variation in Obesity at the State Level in the All of Us Research Program. Preventing Chronic Disease, 2021, 18, E104.	3.4	6
45	Role of the gut microbiome in cardiovascular drug response: The potential for clinical application. Pharmacotherapy, 2022, 42, 165-176.	2.6	5
46	Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. Journal of Translational Medicine, 2013, 11, 12.	4.4	4
47	Planning and Conducting a Pharmacogenetics Association Study. Clinical Pharmacology and Therapeutics, 2021, 110, 688-701.	4.7	4
48	The essential research curriculum for doctor of pharmacy degree programs – 2021. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	4
49	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Research and Clinical Practice, 2014, 104, 363-369.	2.8	3
50	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development, 2018, 3, 319-329.	0.7	3
51	Unveiling the Genetic Architecture of Human Disease for Precision Medicine. Clinical and Translational Science, 2019, 12, 3-5.	3.1	3
52	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	2.2	3
53	Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines. Clinical and Translational Science, 2019, 12, 560-563.	3.1	1
54	Genome-Wide Association Study Identifies Variation in <i>ABO</i> As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39.	1.4	1

JASON H KARNES

#	Article	IF	CITATIONS
55	Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches. Frontiers in Pharmacology, 2021, 12, 812830.	3.5	1
56	PharmGKB summary. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	1.5	1
57	A Study of Immunogenetic Associations with Peanut Allergy Utilizing a Novel DNA Repository. Journal of Allergy and Clinical Immunology, 2016, 137, AB25.	2.9	0
58	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
59	Reply to Non and Chang: Challenging the Role of Genetic Ancestry in Explaining Racial/Ethnic Health Disparities. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 398-399.	5.6	0